Insmed (INSM) – Investment Analysts’ Weekly Ratings Updates

Several analysts have recently updated their ratings and price targets for Insmed (NASDAQ: INSM):

• 12/19/2025 – Insmed is now covered by analysts at Truist Financial Corporation. They set a “buy” rating and a $202.00 price target on the stock.
• 12/18/2025 – Insmed had its price target lowered by analysts at HC Wainwright from $240.00 to $230.00. They now have a “buy” rating on the stock.
• 12/18/2025 – Insmed was given a new $241.00 price target on by analysts at Cowen Inc.
• 12/18/2025 – Insmed was given a new $212.00 price target on by analysts at Mizuho.
• 12/18/2025 – Insmed was given a new $203.00 price target on by analysts at Wedbush.
• 12/18/2025 – Insmed had its price target lowered by analysts at Royal Bank Of Canada from $215.00 to $195.00. They now have an “outperform” rating on the stock.
• 12/18/2025 – Insmed was given a new $195.00 price target on by analysts at Wells Fargo & Company.
• 12/18/2025 – Insmed had its “outperform” rating reaffirmed by analysts at Leerink Partners.
• 12/18/2025 – Insmed had its “outperform” rating reaffirmed by analysts at Citigroup Inc..
• 12/18/2025 – Insmed was given a new $167.00 price target on by analysts at Wolfe Research. They now have an “outperform” rating on the stock.
• 12/18/2025 – Insmed was upgraded by analysts at Truist Financial Corporation to a “strong-buy” rating.
• 12/18/2025 – Insmed had its price target lowered by analysts at TD Cowen from $269.00 to $241.00. They now have a “buy” rating on the stock.
• 12/18/2025 – Insmed had its price target lowered by analysts at Guggenheim from $230.00 to $221.00. They now have a “buy” rating on the stock.
• 12/16/2025 – Insmed had its price target raised by analysts at Wells Fargo & Company from $217.00 to $234.00. They now have an “overweight” rating on the stock.
• 12/16/2025 – Insmed had its price target raised by analysts at Cantor Fitzgerald from $216.00 to $230.00. They now have an “overweight” rating on the stock.
• 12/15/2025 – Insmed had its price target raised by analysts at The Goldman Sachs Group, Inc. from $225.00 to $258.00. They now have a “buy” rating on the stock.
• 12/11/2025 – Insmed had its price target raised by analysts at TD Cowen from $231.00 to $269.00. They now have a “buy” rating on the stock.
• 12/10/2025 – Insmed was given a new $269.00 price target on by analysts at Jefferies Financial Group Inc..
• 12/10/2025 – Insmed had its “buy” rating reaffirmed by analysts at Cowen Inc.
• 12/4/2025 – Insmed was given a new $263.00 price target on by analysts at Redburn Partners.
• 12/4/2025 – Insmed was upgraded by analysts at Rothschild Redb to a “strong-buy” rating.
• 12/4/2025 – Insmed is now covered by analysts at Rothschild & Co Redburn. They set a “buy” rating and a $263.00 price target on the stock.
• 12/1/2025 – Insmed had its price target raised by analysts at Mizuho from $196.00 to $256.00. They now have an “outperform” rating on the stock.
• 11/20/2025 – Insmed had its “buy” rating reaffirmed by analysts at Cowen Inc.
• 11/20/2025 – Insmed had its price target raised by analysts at TD Cowen from $223.00 to $231.00. They now have a “buy” rating on the stock.
• 10/31/2025 – Insmed had its price target raised by analysts at The Goldman Sachs Group, Inc. from $196.00 to $225.00. They now have a “buy” rating on the stock.
• 10/31/2025 – Insmed had its price target raised by analysts at Royal Bank Of Canada from $139.00 to $215.00. They now have an “outperform” rating on the stock.
• 10/31/2025 – Insmed had its price target raised by analysts at UBS Group AG from $194.00 to $223.00. They now have a “buy” rating on the stock.
• 10/31/2025 – Insmed had its price target raised by analysts at Wells Fargo & Company from $171.00 to $217.00. They now have an “overweight” rating on the stock.
• 10/30/2025 – Insmed had its “buy” rating reaffirmed by analysts at Cowen Inc.
• 10/29/2025 – Insmed was given a new $196.00 price target on by analysts at Mizuho.
• 10/28/2025 – Insmed is now covered by analysts at Cantor Fitzgerald. They set an “overweight” rating and a $192.00 price target on the stock.
• 10/27/2025 – Insmed had its price target raised by analysts at Bank of America Corporation from $142.00 to $187.00. They now have a “buy” rating on the stock.

Insider Buying and Selling

In other news, insider Michael Alexander Smith sold 27,130 shares of Insmed stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $183.78, for a total value of $4,985,951.40. Following the transaction, the insider owned 54,902 shares in the company, valued at approximately $10,089,889.56. The trade was a 33.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 30,000 shares of Insmed stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $194.00, for a total value of $5,820,000.00. Following the completion of the transaction, the insider directly owned 36,461 shares in the company, valued at $7,073,434. This trade represents a 45.14% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 157,829 shares of company stock valued at $30,266,463 in the last 90 days. 3.00% of the stock is owned by company insiders.

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.